Analysts' average 12-month price target for Spruce Biosciences is $140.
Get informed when a big investor buys or sells
+ Follow$47.07
3 analysts in the last 4 months
High: $150 | Low: $123
No recommendations in the last 4 months.
As of the most recent data, SPRB shows a target price of $140. Scroll down for historical charts and peer comparison views.
If Spruce Biosciences moved to the average analyst target of $140, shares would be roughly 192.5% higher than $47.07. Treat that as a sentiment and modeling checkpoint rather than a precise forecast, and weigh it against your own view of Spruce Biosciences's earnings trajectory.
Besides this target price page, Stockcircle has Spruce Biosciences's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect target price (currently $140) with ownership activity and broader fundamentals.
Spruce Biosciences's target price is $140; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.